Provided by Tiger Trade Technology Pte. Ltd.

Prime Medicine, Inc.

3.67
-0.1200-3.17%
Pre-market: 3.700.0300+0.82%04:01 EDT
Volume:1.52M
Turnover:5.58M
Market Cap:662.47M
PE:-2.71
High:3.79
Open:3.79
Low:3.61
Close:3.79
52wk High:6.94
52wk Low:1.11
Shares:180.51M
Float Shares:99.80M
Volume Ratio:0.80
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3521
EPS(LYR):-1.3521
ROE:-146.81%
ROA:-40.68%
PB:5.48
PE(LYR):-2.71

Loading ...

Company Profile

Company Name:
Prime Medicine, Inc.
Exchange:
NASDAQ
Establishment Date:
2019
Employees:
146
Office Location:
60 First Street,Cambridge,Massachusetts,United States
Zip Code:
02141
Fax:
- -
Introduction:
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.

Directors

Name
Position
Allan Reine
Chief Financial Officer,Chief Executive Officer and Director
Jeffrey Marrazzo
Director and Executive Chair
David Schenkein
Director
Kaye Foster
Director
Michael Kelly
Director
Robert Taylor NELSEN
Director
Thomas Cahill
Director
Wendy Chung
Director

Shareholders

Name
Position
Allan Reine
Chief Financial Officer,Chief Executive Officer and Director
Ann Lee
Chief Technical Officer
Carman Alenson
Chief Accounting Officer
Jeffrey Marrazzo
Director and Executive Chair